COSCIENS BIOPHARMA INC (CSCI.CA) Stock Price & Overview
TSX:CSCI • CA22112H1010
Current stock price
The current stock price of CSCI.CA is 2.68 CAD. Today CSCI.CA is down by -4.29%. In the past month the price increased by 143.64%. In the past year, price decreased by -39.78%.
CSCI.CA Key Statistics
- Market Cap
- 8.522M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.47
- Dividend Yield
- N/A
CSCI.CA Stock Performance
CSCI.CA Stock Chart
CSCI.CA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CSCI.CA. When comparing the yearly performance of all stocks, CSCI.CA is a bad performer in the overall market: 92.6% of all stocks are doing better.
CSCI.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CSCI.CA. CSCI.CA may be in some trouble as it scores bad on both profitability and health.
CSCI.CA Earnings
CSCI.CA Forecast & Estimates
CSCI.CA Groups
Sector & Classification
CSCI.CA Financial Highlights
Over the last trailing twelve months CSCI.CA reported a non-GAAP Earnings per Share(EPS) of -4.47. The EPS increased by 38.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.33% | ||
| ROE | -269.6% | ||
| Debt/Equity | 0.5 |
CSCI.CA Ownership
CSCI.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 588.588M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 407.854M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 151.996M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.52 | 52.754M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 50.886M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 44.153M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 3.39 | 33.125M | ||
| RVX | RESVERLOGIX CORP | N/A | 31.617M | ||
| MPH | MEDICURE INC | N/A | 14.094M | ||
| HEM | HEMOSTEMIX INC | N/A | 13.845M | ||
| TELO | TELO GENOMICS CORP | N/A | 6.026M | ||
| QPT | QUEST PHARMATECH INC | N/A | 5.92M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About CSCI.CA
Company Profile
COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Company Info
IPO: 1995-12-19
COSCIENS BIOPHARMA INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO CA
Employees: 21
Phone: 18439003201
COSCIENS BIOPHARMA INC / CSCI.CA FAQ
What does CSCI do?
COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
What is the current price of CSCI stock?
The current stock price of CSCI.CA is 2.68 CAD. The price decreased by -4.29% in the last trading session.
What is the dividend status of COSCIENS BIOPHARMA INC?
CSCI.CA does not pay a dividend.
How is the ChartMill rating for COSCIENS BIOPHARMA INC?
CSCI.CA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for COSCIENS BIOPHARMA INC?
COSCIENS BIOPHARMA INC (CSCI.CA) will report earnings on 2026-05-11.